ChemoTech has today made the strategic decision to create a fully owned subsidiary for its Animal Care business.

The new entity will be a subsidiary fully owned by Scandinavian ChemoTech AB. The intention of creating a new entity, is to enable diversified strategies for the animal- and human care businesses respectively, while maintaining the synergies in technology and overhead administration.

"We believe this decision will have a strong impact on the two businesses as it will strengthen the focus for each business area. It will also allow for separate and focused tracks in the further development of strategies, partnerships and alliances to fully reach their anticipated potentials." - says Mohan Frick, CEO

For more information, please contact:

Mohan Frick, Co-Founder and CEO

Phone: +46 (0)10-218 93 00

[email protected]

Certified Adviser: Västra Hamnen Corporate Finance AB, Tel: +46 40 200 250, E-mail: [email protected]

This information is such information which Scandinavian ChemoTech AB (publ) are obligated to make public according to EU's market abuse regulation and the law of securities market. The information was submitted by the agency of above stated contact person, to be made public on Tuesday July 7th 2020 at 11.00 (CET).

Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, tumour specific electroporation, available for treatment of both for humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where tumour specific electroporation can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Västra Hamnen Corporate Finance AB is the company's Certified Adviser. Read more at:,c3150043

(c) 2020 Cision. All rights reserved., source Press Releases - English

Source link